Related references
Note: Only part of the references are listed.Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Takashi Nakada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Antibody Drug Conjugates: Nonclinical Safety Considerations
Mary Jane Masson Hinrichs et al.
AAPS JOURNAL (2015)
Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks
Gillian C. Bethune et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2015)
Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
Gregory S. Hamilton
BIOLOGICALS (2015)
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M. C. van der Lee et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
Michinori Ogura et al.
CANCER SCIENCE (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Cathepsin B: Multiple roles in cancer
Neha Aggarwal et al.
PROTEOMICS CLINICAL APPLICATIONS (2014)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
Hee Eun Lee et al.
EUROPEAN JOURNAL OF CANCER (2013)
Monoclonal antibody-based therapies in cancer: Advances and challenges
Puja Sapra et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
Ajay K. Gopal et al.
BLOOD (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Hans K. Erickson et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors
Yoshinobu Shiose et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma
M Niedergethmann et al.
PANCREAS (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Share Paper
